Schrödinger, Inc. has announced a collaboration with Sanofi SA (ADR) (NYSE:SNY), with the aim of providing a computational, comprehensive drug design. The design will aid in coming up with over ten drugs discovery program in which Schrödinger will receive $120 million.
Though Computer Aided Design has played a significant role in many industries, it has not made a significant impact in the drug discovery field. Despite that, Schrödinger has previously had a few breakthroughs particularly in protein structure determination. This and the determination of potency have created chances for a transformative impact on drug discovery.
Sanofi’s collaboration with Schrödinger will give Sanofi access to first rate computational design resources and cutting edge technology. This will create an avenue for advanced research. The company also plans on optimizing its ventures with the new cutting edge technology that was previously absent. This had been a limiting factor for the firm.
The collaboration is also aimed at bringing out the sleeping potential within both companies and making more breakthroughs in the pharmaceutical industry. The grant will allow work without limitation of technology.
Dr. Farid, who is Schrödinger’s President, expressed the company’s excitement in collaborating with Sanofi. He also stated that the company is looking forward to a long term partnership and many breakthroughs expected to manifest especially from their combined resources.
The partnership move comes as a breather for Sanofi, as the company was having problems in its scientific endeavors. Political influences had made the company slow down as well as having to downsize its cancer research and development. These and a few more factors had led to slow progress for the determined company.
Schrödinger’s collaboration with Sanofi SA (ADR) (NYSE:SNY) is expected to create optimized conditions for both companies to test out their skills on a wider basis. The availability of ultra-modern technology, as well as perpetual innovation, will allow both companies to effectively advance and expand their scope of research. These opportunities will increase the chances for advanced breakthroughs.